2018 POSTER PRESENTATIONS

Room: Grand Ballroom

Poster Presenters noted with † are Student Fellows.
Poster Presenters noted with * are Conference Speakers.

Presenting Wednesday through Friday

AbCellera Biologics, Inc.
101.     A Versatile, High-Throughput Single Cell Screening Platform for the Generation of Fully Human Antibodies from Natural Immune Repertoires; Presented by Kevin H.*

AbCellera Biologics, Inc.
102.     Unlocking Challenging Targets: Deep Screening of Natural Immune Repertoires at the Single-Cell Level for Therapeutic Antibody Discovery; Presented by Kevin H.*

Agilent Technologies
103.     Determining Mechanisms of Mitochondrial Toxicity Using Agilent Seahorse XF Technology; Presented by Pamela S.

Ain Shams University
104.     Potential Therapeutic Implications of Hematopoietic Stem Cell Gene Therapy in Correction of Mutation-Causing Human Beta-Thalassemia; Presented by Dina G.†

Antibody Solutions
105.     A Novel Interface Targeted Discovery Engine for the Generation of Monoclonal Antibodies Against an Immune Checkpoint Cell Membrane Protein; Presented by John K.

AssayQuant Technologies, Inc.
106.     Sensors for Continuous Monitoring of Protein Kinase and Phosphatase Activity; Presented by Erik S.*

Avacta Life Sciences
107.     Generation of a Novel Affimer Biotherapeutic Targeting the PD-L1 Pathway to Deliver a Myeloid Selective Toxin to the Tumour Micro-Environment; Presented by Matthew V.

BellBrook Labs, LLC
108.     The Transcreener® ADP[2] Assay: A Universal Kinase Assay for HTS and Lead Optimization; Presented by Meera K.

BellBrook Labs, LLC
109.     Development of a High Throughput Transcreener Assay to Explore the Family of Ectonucleotidases Enzyme Family; Presented by Meera K.

BellBrook Labs, LLC
110.     Sensitive Detection of PRMT4 Using Physiological SAM with the AptaFluor Methyltransferase Assay; Presented by Meera K.

Biodesy, Inc.
111.     Second-Harmonic Generation Based Detection of Ligand-Induced Conformational Changes in STING; Presented by David S.

Biological Research Centre of the Hungarian Academy of Sciences
112.     Predicting Antibiotic Resistance by Targeted Mutagenesis in Pathogenic Bacteria; Presented by Akos N.

Biomatters, Inc.
113.     Advanced Antibody Analysis of NGS and Sanger Data from Selection and Screening Projects Accelerate Therapeutic Antibody Discovery; Presented by Cecilie B.

BPS Bioscience, Inc.
114.     Improving Immunotherapy Through Assays of the Extracellular Adenosine Pathway; Presented by Pavel S.

Broad Institute of MIT and Harvard
115.     Development of Subtype-Specific T-Type Calcium Channel Modulators for CNS Disorders; Presented by Joshua S.

Cellecta, Inc.
116.     Cell Barcoding Libraries and Targeted Gene Expression for Single-Cell Genetic Analysis; Presented by Paul D.*

CELLGENTEK
117.     Development of Interleukin-32 Gamma-Engineered Natural Killer Cells; Presented by Hyeran S.

Cellular Technology Limited
118.     A Novel Fluorescence Based High-Throughput Target Cell Visualization Assay for Measuring Cell-Mediated Cytotoxicity; Presented by Villian N.

Charles River
119.     A Translational Platform Using Primary Human Immune Cells In Vitro, Syngeneic and Humanized Models In Vivo to Support and Advance Immune-Oncology Drug Discovery; Presented by Barbara K.

Charles River
120.     Two In Vitro Assays Relevant to Lung Fibrosis for Evaluating the Potency and Efficacy of Prospective Anti-Fibrotic Drugs; Presented by Lieke G.*

ChemBridge Corporation
121.     Synthetic Macrocycle Library with Potential to Find Hits for CNS Drug Discovery Programs; Presented by Duncan B.

Chemspace, Inc.
122.     Compound Libraries on Chemspace: An Approach to Chart Useful Regions in Available Chemical Space; Presented by Yurii M.

Chulalongkorn University
123.     5-Methylcytosine Containing CG Decamer as Z-DNA Embedded Sequence for a Potential Z-DNA Binding Protein Probe; Presented by Vorasit V.

CILcare
124.     Role of Melatonin in the Prevention of Noise-Induced Hearing Loss; Presented by Sylvie C.*

Clarivate Analytics
125.     Integrated Machine Learning Analysis of GWAS Loci to Assist Prioritization of Causal Genes for Parkinson's Disease; Presented by Cheng F.

Confluence Discovery Technologies
126.     Development of Mitogen-Activated Protein Kinase Activated Protein Kinase-2 (MK2) Inhibitors Designed to Selectively Inhibit the p38/MK2 Complex; Presented by Joseph M.

Confluence Discovery Technologies
127.     Using the Novel KINect Platform to Discover Drugs Targeting the Human Protein Kinase Cysteinome; Presented by William T.

Deutsches Elektron Synchrotron (DESY)
128.     Characterization of Proteins of the SPI-1 Type III Secretion System of Salmonella thyphimurium; Presented by Ivonne B.†

Domain Therapeutics NA
129.     bioSensAll™: Opening Up New Frontiers in RTK Drug Discovery; Presented by Guilhem D.

Eurofins Pharma Discovery Services
130.     Interrogating Allosteric Interactions Using Multiple Readouts for GPCRs; Presented by Daniel B.

Eurofins Pharma Discovery Services
131.     Multiple Pathway Activation in a Human M4 Muscarinic Receptor Cell-Based Assay; Presented by Carsten B.

Eurofins Pharma Discovery Services
132.     Binding and Functional Analysis - Complementary Approaches in Safety Pharmacology; Presented by Thierry J.

Eurofins Pharma Discovery Services
133.     Combining the Power of Different Profiling Approaches to Better Understand the Activity of Kinase Inhibitor Drugs; Presented by Alastair K.

Gachon University
134.     Daurinol: A Novel Agent to Treat Inflammatory Arthritis via Induction of Regulatory T Cells and Suppression of Helper T Cells; Presented by Jungmin A.

GenScript USA, Inc.
135.     Integrated Antibody Drug Discovery and Development: From Target to IND Application; Presented by Sasidhar M.

Glycotope GmbH
136.     Tumor-Specific Carbohydrate Antigens as Preferable Targets for Novel Antibody Constructs; Presented by Timo L.

GVK Biosciences Pvt. Ltd.
137.     Novel In Vitro Label-Free Medium to High-Throughput Screening Assays by RapidFire Mass Spectrometry; Presented by Lakshman R.

Integral Molecular
138.     Discovery of Highly-Specific Claudin 6 Antibodies for Targeting Cancer; Presented by Ross C.

Integral Molecular
139.     High-Resolution Epitope Mapping Reveals Antibody Mechanism of Action and Strengthens Intellectual Property; Presented by Joseph R.*

Integral Molecular
140.     Screening the Membrane Proteome to Determine Antibody Specificity and Discover New Immuno-Oncology Targets; Presented by Sharon W.

Invivotek
141.     Time and Strain-Related Variables of Multiple Dietary-Based Mouse NASH Models; Presented by Michael H.

iTeos Therapeutics
142.     EOS100850, an Insurmountable and Non-Brain Penetrant A2A Receptor Antagonist, Inhibits Adenosine-Mediated T Cell Suppression, Demonstrates Anti-Tumor Activity and Exhibits Best-in-Class Characteristics; Presented by Jakub S.

Key Organics Ltd.
143.     New BIONET Compounds for CNS Diseases: Potent Brain Penetrant Compounds with Improved Physical Property Profile; Presented by Steve B.

Key Organics Ltd.
144.     Building a Diverse and Experimentally-Curated Fragment Library; Presented by Steve B.

KU Leuven
145.     Studying GPCR Signaling Using Cell-Based Impedance Technology; Presented by Jordi D.

Labcyte, Inc.
146.     Detection of Phospho-Akt (Ser 473) as an Indication of PI3K Pathway Activation in MCF7 Cells Using the Labcyte Echo® Liquid Handler and Cisbio's HTRF® Cellular Assay Kit; Presented by Wayne L.

Labcyte, Inc.
147.     High Throughput Multiplexed Apoptosis Assays Using the Labcyte Echo® Liquid Handler and the IntelliCyt® iQue Screener HD; Presented by Ward S.

Lifesensors, Inc.
148.     Proteomic Discovery of Ubiquitylated Biomarkers for Neurodegenerative Disease; Presented by Peter F.*

Lifesensors, Inc.
149.     New Developments in Ubiquitomics: Discovery of Poly-Ubiquitylated Proteins by Novel Chain-Selective TUBEs; Presented by Dominic V.

Ligand Pharmaceuticals, Inc.
150.     Use of High Throughput SPR to Validate Next Generation OmniChickens; Presented by Kimberley B.

Ligand Pharmaceuticals, Inc.
151.     Utilization of the OmniChicken™ Platform to Derive Functional Therapeutic Antibody Candidates Against a Transmembrane Protein Target; Presented by Darlene P.

Los Alamos National Laboratory
152.     A Resistance-Proof Radioimmunotherapeutic Antibiotic Cocktail Against Plague; Presented by Antonietta L.

Masaryk University
153.     Furo[3,2-b]pyridine - A Novel Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway; Presented by Vaclav N.†

Massey University
154.     Characterization of Furazolidone-Resistant Escherichia coli Mutants Reveals Novel Reductase Activity of the AhpF Protein; Presented by Van Hung Vuong L.†

Medivir AB
155.     Selective Suppression of Regulatory T-Cell Development Using Small Molecule Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1); Presented by Karolina E.*

Medivir AB
156.     Identification and Characterization of Novel Small Molecule Inhibitors of Ubiquitin Specific Peptidase 1 (USP1); Presented by Daniel J.

MercaChem BV
157.     Tankyrase Inhibitor Development: Evidence for Potential in Cancer Immune Therapy; Presented by Luc V.

ModiQuest Research B.V., An ImmunoPrecise Company
158.     Selection of a Large Panel of Lead Antibody Candidates by High-Throughput Multiplex Screenings; Presented by Jos R.

Multispan, Inc.
159.     Measure β-Arrestin Signaling Through Native GPCRs in High Throughput; Presented by Lisa M.*

Myongji University
160.     Novel Carbapenemase Form Gram-Negative Pathogens as a Drug Target; Presented by Kwang Seung P.†

National Institutes of Health, National Center for Advancing Translational Sciences
161.     Drug Repurposing Approach Identifies Synergistic Drug Combination Against Multi-Drug Resistant Acinetobacter baumannii; Presented by Yu-Shan C.

National Institutes of Health, National Center for Advancing Translational Sciences
162.     Identifying New Drug Targets by Illuminating the Druggable Genome; Presented by Karlie S.

Oxford Genetics Limited
163.     Optimised CRISPR Vector Systems and Automated Library Construction Technologies for High-Throughput Cell Line Engineering and Screening Applications; Presented by Richard P.

Oxford Genetics Limited
164.     A High Throughput Automated Platform for CRISPR Mediated Genomic Editing; Presented by Lee S.

PerkinElmer
165.     Evaluating PD-1 and PD-L1 Blocking Antibodies Using Human and Mouse Binding Kits; Presented by Lindsay N.

PerkinElmer
166.     LANCE Ultra TR-FRET-Based Detection and Modulation of Phosphorylated Protein Expression in Human Cells; Presented by Lindsay N.

Promega Corporation
167.     Specific Detection of Target Cell Killing in Mixed Cultures Using HiBiT; Presented by Neal C.

Promega Corporation
168.     Quantitative Live-Cell Characterization of PROTAC-Induced Degradation and Mechanism of Action; Presented by Steven E.

Promega Corporation
169.     Broad Kinome Selectivity and Residence Time Profiling in Living Cells Using BRET; Presented by Matthew R.*

ProQinase GmbH
170.     New Spontaneous and Carcinogen-Induced Mouse-Derived Isograft (MDI) Tumor Models for Immune Therapeutic Approaches; Presented by Katrin S.

Reaction Biology Corporation
171.     Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells; Presented by Yuren W.*

St. Jude Children's Research Hospital
172.     Glucose-Dependent Regulation of Pregnane X Receptor Is Modulated by AMP-Activated Protein Kinase; Presented by Peter O.

Stanford University
173.     Targeting MRSA Biofilms and Persister Cells with a New Antibiotic-Oligoarginine Conjugate; Presented by Alexandra A.†

Sygnature Discovery Ltd.
174.     Application of Different Neuronal Cell Models to Investigate Glutamate-Induced Excitotoxicity in Drug Discovery; Presented by John U.

Taipei Medical University
175.     Indole Based Phenylacrylamides with Potent HDAC Inhibitory, Anti-Proliferative and Anti-Angiogenic Activities; Presented by Samir M.†

Transomic Technologies, Inc.
176.     A Genome-Wide Arrayed CRISPR Library for Studying Combinatorial Gene Interactions; Presented by Blake S.

Tufts University
177.     Genetic Mechanisms of a Bacterial Predator Targeting Gram Negatives; Presented by Miles D.

Université de Sherbrooke
178.     A Systematic Exploration of Macrocyclization in Apelin-13; Presented by Kien T.†

University College London
179.     Use of Neuronal Oscillations in Brain Slices as a Biomarker to Characterise Drugs that Affect Cognitive Function; Presented by Thomas S.

University of Bergen
180.     Druggable Genome in Attention Deficit/Hyperactivity Disorder and Its Co-Morbid Conditions: New Avenues for Treatment; Presented by Kai W.†

University of British Columbia
181.     Peptidisc: A Simple Solution for Trapping and Stabilizing Membrane Proteins Without Detergent; Presented by Franck D.

University of California, San Diego
182.     A Single Small Molecule Alleviates Tumor Burden by Targeting Dual Regulators of the 26S Proteasome; Presented by Sourav B.

University of North Texas Health Science Center
183.     Design and Synthesis of Novel Irreversible Inhibitors of NGLY1; Presented by Nigam M.

University of Toronto at Scarborough
184.     Single Domain Antibodies Targeting Motility of Enteric Pathogens Offers Protection in Livestock and Food Animals; Presented by Valencio S.

Vaccinex, Inc.
185.     Use of Mammalian Virus Display to Select Antibodies Specific for Complex Membrane Antigens; Presented by Maria S.

Vanderbilt University
186.     Pharmacological WDR5 WIN Site Inhibition in MLL Leukemia; Presented by Erin A.†

ZoBio B.V.
187.     Design Principles of the ZoBio Fragment Library: Core Diversity and Synthetic Tractability; Presented by Jan S.

ZoBio B.V.
188.     Protein Domain Trapping: High Throughput Protein Engineering to Enable Biophysics and Structural Biology Based Drug Discovery; Presented by Gregg S.

 

Presenting Wednesday through Thursday (morning)

Gyros Protein Technologies
201.     Parallel Synthesis Optimization of Cyclic Peptides for Therapeutic Development; Presented by Cyf R.

H. Lee Moffitt Cancer Center and Research Institute
202.     Landscape of Active Deubiquitinating Enzymes (DUB) in KRAS Mutant Lung Cancer; Presented by Shikha M.

Kyungpook National University
203.     ASM Regulates the Autophagic Process by Controlling Lysosomal Biogenesis in Alzheimer's Disease; Presented by Jae-sung B.

Kyungpook National University
204.     Neuronal SphK1 Acetylates COX2 and Contributes to Pathogenesis in a Model of Alzheimer's Disease; Presented by Hee Kyung J.

National University of La Rioja
205.     Omega-3 Fatty Acids Administration Attenuates Neuropathic Pain Behaviors in Rats and Promotes Nerve Functional Recovery; Presented by Santiago U.†

Phanes Therapeutics, Inc.
206.     Discovery of Anti-Apelin Mabs as Potential Therapies for Solid Tumors and Diabetic Retinopathy; Presented by Natalie W.†

RXi Pharmaceuticals
207.     The Use of Self-Delivering RNAi (sd-rxRNAs) to Enhance NK Cell Cytotoxicity; Presented by Melissa M.

Salipro Biotech AB
208.     The Salipro System for Detergent-Free Stabilization of Membrane Proteins; Presented by Andre H.

TetraGenetics, Inc.
209.     TetraExpress™: A Platform for the Robust Expression and Purification of Correctly Folded and Functional Membrane Proteins; Presented by Alka A.

University of Queensland
210.     Macrocyclization of Peptides by Selenoether Bridges: Synthetic Methods and Applications; Presented by Aline D.

 

Presenting Thursday (afternoon) through Friday

Albany Molecular Research, Inc.
301.     Comparison of Neisseria Gonorrhoeae Minimum Inhibitory Concentrations Obtained Using Agar Dilution Versus Microbroth Dilution Methods; Presented by Rachael J.

American University of Beirut
302.     Unveiling the Native Fingerprint of Bradykinin (B2) and Thromboxane (TP) Receptors Oligomerization in Vascular Cells; Presented by Oula D.†

Cayman Chemical Company
303.     Study of Novel Aspartate Aminotransferase Inhibitor Binding Mechanism Through Structure-Based Mutational Analysis; Presented by Zahra A.

Edelris SAS
304.     Exploring New Chemical Space Towards Hit Generation; Presented by Eric J.

Food and Drug Administration
305.     Comparative Toxicity of Regorafenib and Its Pharmacologically Active Metabolites in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes and Hepatocytes; Presented by Qiang S.

Harvard Medical School
306.     Using Protein Engineering to Map the Interface Between the Hormone Adiponectin and Its Receptor; Presented by Roberta P.

Life Chemicals, Inc.
307.     Identification of Biologically Active Compounds as a Result of Screening Life Chemicals Compound Libraries; Presented by George B.

Life Chemicals, Inc.
308.     Fragment Libraries for Drug Discovery; Presented by George B.

NeoProteomics, Inc.
309.     High-Resolution Hydroxyl Radical Protein Footprinting Introduction and Workflow; Presented by John S.

TetraGenetics, Inc.
310.     A Multiplatform Strategy for the Discovery of Conventional Monoclonal Antibodies that Inhibit the Voltage-Gated Potassium Channel Kv1.3; Presented by Yelena B.

Tulane University
311.     Yeast as a Platform to Study Adenosine Receptor Signaling; Presented by Abhinav J.†

University of Oxford
312.     Biotechnology: Pipeline Developments; Presented by Aleksandra S.†

Universitѐ De Rouen
313.     Pharmacological Profiling of a New Melatonin Binding Site: MTx; Presented by Preety S.†

Westborough High School
314.     Non-Specific Chemical Descriptor Based QSAR; Presented by Ananthan S.†



cta-prelim-agenda

View By: